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The evaluation of b-catenin expression in adenocarcinoma of the esophagogastric 
junction and its influence on cancer progression.
Sixty-one patients who were diagnosed with adenocarcinoma of the esophagogastric 
junction were examined. We evaluated b-catenin distribution in the cell membrane 
and the cell nucleus in adenocarcinoma of the esophagogastric junction type 1 
and type 3.
Our findings showed lack of a statistically significant difference in evaluation of ad-
enocarcinoma type 1 and type 3 aggressiveness. However, we found a statistically 
significant association with the T and N stage, although we did not find an effect 
of them on patient survival. 
Patients with cellular membrane and cell nucleus staining comprise a group of pa-
tients with higher risk of malignancy progression in adenocarcinoma of the esoph-
agogastric junction types 1 and 3.
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Introduction
In the last decades the incidence of esophagogas-
tric junction adenocarcinoma has been rising. At the 
same time, the incidence of squamous cell carcinoma 
has been declining or remains the same. Despite radi-
cal surgical and radio/chemotherapy, survival rates are 
not satisfactory and the risk and evaluation of carcino-
ma relapse are uncertain [1, 2]. The identification of 
patients with higher risk of carcinoma relapse would 
facilitate therapeutic treatment strategy significantly. 
Due to progress in immunohistochemistry and 
molecular diagnostics, the role of cell adhesion mole-
cules has become more accurate and understandable. 
b-catenin was described as an element of the E-cadher-
in/catenin complex. In healthy cells catenin is united 
with adherin, but its action depends on APC (adeno-
matous polyposis coli) and phosphorylation by ser-
ine-threonine kinase GSK-3B. In the event of muta-
tions, the phosphorylation process becomes disturbed 
and b-catenin passes into the cell’s nucleus with LEF 
(lymphocyte enhancer factor)/TCF (T cell factor). It 
turns out that such action may decode the reaction 
which through MMP-7 (matrix metalloproteinase 7), 
cyclin D1, MDR 7 (multidrug resistance gene) and 
later through AD-1 and fra-1 may start the process 
of carcinogenesis or tumor progression [3, 4]. The role 
of the E-cadherin/catenin complex in adenocarcinoma 
of the esophagogastric junction is unclear. The aim of 
this study is to assess the influence of b-catenin expres-
sion on the metastatic potential of adenocarcinomas 
localized in the esophagogastric junction. 
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Material and methods
Patients
Sixty-one patients with confirmed adenocarcinoma 
of the gastroesophageal junction were included in the 
study. According to the Siewert and Stein classifica-
tion [5] they were divided into three groups: patients 
with adenocarcinoma related to Barrett esophagus 
(AEG type I), adenocarcinoma of cardia (AEG type 
II) and subcardial adenocarcinoma (AEG type III). 
Only patients with type I and type III adenocarci-
noma were included in this study because sometimes 
differentiation between type 2 and 3 in stage T3 or 
T4 makes difficulties in assessment [5]. The TNM 
UICC and Lauren classification was used for assess-
ment of the disease stage [6, 7]. Patients with AEG1 
tumors underwent transmediastinal esophagectomy, 
proximal stomach and lymphadenectomy in the pos-
terior mediastinum and celiac axis. An extended total 
gastrectomy with resection of the distal esophagus 
and D2 lymphadenectomy with transhiatal lymph-
adenectomy of the inferior mediastinum was the pro-
cedure for patients with AEG3 tumors. In total 1130 
lymph nodes were removed during surgery, on aver-
age 22 lymph nodes per patient (range 8-58 lymph 
nodes). In 60 cases surgery was radical (R0), while 
1 case was classified as R1. The mean follow-up time 
for the 61 patients was 27.4 months, with a range 
of 1-96.7 months. Table I shows clinical and histo-
pathologic outcomes of patients.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue speci-
mens were cut into 6 μm thick section which were 
placed onto silanized slides, then deparaffinized 
and rehydrated. Antigen retrieval was performed 
by means of a citric acid solution, pH 6.0, which 
was heated in a microwave oven for 1 × 15 min, at 
650 W. Endogenous peroxidase activity was blocked 
with a 0.2% hydrogen peroxide solution. The pri-
mary antibody was the b-catenin specific HEC-D1 
monoclonal antibody (Takara Biomedicals, Takara 
Shuzo Japan) that was incubated for 1.5 h at room 
temperature at a dilution of 1 : 1000. Detection of 
the bound antibody was carried out with the avi-
din-biotin complex peroxidase method (ABC Elite 
kit, Eliot Burlingame CA), followed by staining with 
the peroxidase substrate 3,3-diaminobenzidine tetra-
chloride (DAB) (Sigma GmbH, Deisenhofen Germa-
ny). A light hematoxylin stain was used as the coun-
terstain. As a negative control, the primary antibody 
was replaced with phosphate-buffered saline. Normal 
esophagus mucosa with membranous (M+) and no 
nuclear (N–) expression in the tissue section served 
as a positive control. Membranous (M) and nuclear 
expression of b-catenin was assessed. Membranous 
staining for b-catenin was classified as a normal 
(3+), reduced (moderate) (2+), weak (1+) or neg-
ative (0). The percentage proportion of stained cells 
with complete membranous staining was recorded in 
the following categories: 0 – 0-10%, 1 – >10-40%, 
2 – 40-90%, 3 – > 90%. In addition, the presence 
and percentage of tumor cells exhibiting clear nucle-
ar staining for b-catenin were noted and classified as 
3+ (> 67% of the tumor cells), 2+ (> 33% and 
< 67% of the tumor cells), 1+ (< 33% of the tumor 
cell nuclei).
Statistics
The correlations between the immunohistochem-
ical expression of membranous b-catenin, nuclear 
catenin staining, survival, grade of differentiation, 
lymph node metastases, tumor size, and Lauren clas-
sification were statistically compared using the χ2 test 
or Fisher’s two-tailed test. Survival probabilities were 
calculated by the Kaplan-Meier method and com-
pared by the log rank test. P values < 0.05 were 
considered to be statistically significant.
Results 
Sixty-one patients diagnosed with adenocarcino-
ma of the esophagogastric junction; 32 of them with 
type 1 and 29 with type 3 (Table I) were analyzed. 
Among patients with type 1, in 21 we found reduc-
tion of cell membrane staining and/or cell nucleus 
staining with anti-b-catenin antibody. In 11 of them 
staining was normal and in 2 of them the reaction 
was negative. In patients with type 3 findings were 
as follows: in 21 patients we found cell membrane 
staining reduction and/or staining of the cell nucleus. 
In 8 patients staining was normal and in 1 patient 
the reaction was negative. Staining of cell nuclei was 
found in 9 patients (in 5 of them there was normal 
cell membrane staining) with type 1 and 11 (in 3 of 
them there was normal cell membrane staining) in 
type 3 (Table II). Among patients with staining re-
duction in type 1 (AEG 1) carcinomas, in 16 of them 
we found an intestinal type, in 2 diffuse type, and 
in 3 a mixed type (according to Lauren’s classifica-
tion). In patients with type 3 (AEG 3) in 15 patients 
we found intestinal type, in 4 patients a diffuse type 
and in 1 patient a mixed type. Staining of cell nuclei 
was found in 6 patients with an intestinal type, in 
2 patients with a mixed type and in 1 patient with 
a diffuse type. Among patients with type 3 (AEG 3), 
in 8 of them we found an intestinal type, in 2 patients 
a diffuse type and in 1 patient a mixed type. In 12 pa- 
tients we found both staining of the cell membrane 
and a nuclear reaction (M+, N+). In 22 patients we 
found a reduction in cell membrane staining (M+, 
N+) and in 8 patients cell nucleus staining. In 19 
patients staining of the cell membrane was classified 
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as stage 3, and in 41 patients no nucleus staining was 
found. 
In 3 patients the results were negative. Staining 
reduction correlated with lymph node metastases 
(p = 0.048) and with T stage (p = 0.041). However, 
staining distribution had no effect on patients sur-
vival. Its connection with Lauren’s classification and 
degree of carcinoma differentiation (Table II) was not 
established.
Discussion
b-catenin is a member of the cell adhesion mol-
ecules, where together with E-cadherin it forms 
a group of interepithelial glycoproteins responsible 
for carrying out the function of adhesion with oth-
er membrane proteins. It has various subcellular lo-
cations occurring in the cell membrane, cytoplasm, 
and cell nucleus. The E-cadherin/catenin complex 
not only plays a role in the cell adhesion process but 
also plays a key role in a signal transmission from 
the external environment and through reaction with 
receptors it may create a particular malignant phe-
notype. Presumably, it may play an important role in 
initiation as well as progression of malignancy, as ev-
idenced by changes in staining of the cell membrane 
as well as the cell nucleus [8, 9, 10, 11]. Loss of the 
epithelium of a mucous membrane’s integrity may 
be an hypothesis about the impact of this complex 
on phenotype change and malignancy progression. 
It is considered that maintenance of cell adhesion is 
possible due to E-cadherin function connected with 
b-catenin in the cytoplasm. Krisdanatu and partners 
reported staining reduction of b-catenin in relation 
to differentiation and shorter survival, not finding it 
to be connected with T stage [9]. Wijahaven et al. 
reported that staining reduction was associated with 
T stage only. They did not observe its association with 
grade. There was no association between esophageal 
adenocarcinoma and carcinoma of a proximal part 
of the stomach [12]. In an earlier study, the authors 
analyzing 24 patients with adenocarcinoma of the 
esophagogastric junction observed a staining reduc-
tion in cell membrane, accumulation in cytoplasm 
(54%, 75%, 67%, 63%) and nucleus relocation 
(25%) for E-cadherin, α-, b-, γ-catenin but without 
a correlation in relation to TNM classification [13]. 
In other reports, the authors note a strong associa-
tion with shorter patient survival, in whom b-catenin 
staining reduction was found. Heaving realized that 
this feature constituted an independent prognostic 
factor, they stated that it may help in identification 
of patients with clinically negative lymph nodes, who 
are at risk of malignant disease progression. Some 
authors note that staining change or lack of it in pa-
tients with lymph node metastases may have a dif-
ferent character than in the original tumor, therefore 
they suggest that staining change may be the result 
of downregulation of other regulation [12, 14]. Bian 
et al. found that staining reduction is associated with 
Table I. Clinical and pathomorphological data of patients with AEG1 and AEG3
grOup aeg1 aeg3 tOtal
N 32 29 61
Sex M : F 26 : 6 23 : 6 61
Age 45-75 33-78 33-78
Follow-up 27.7 (1-96.7) 26.6 (1-91.7) 27.4 (1-96.7)
Differentiation 
Grade G1 : G2 : G3
1 : 16 : 15 0 : 16 : 13 1 : 32 : 28
Lauren type ( I : M : D) 26 : 3 : 2 19 : 4 : 6 45 : 7 : 9
TNM T1N0M0 11
T2N0M0 3
T3N0M0 2
T1N1M0 1
T2N1M0 6
T3N1M0 7
T2N2M0 2
 32
T1N0M0 5
T2N0M0 6
T3N0M0 1
T1N1M0 1
T2N1M0 8
T3N1M0 1
T4N1M0 1
T2N2M0 1
T3N2M0 5
29
T1N0M0 16
T2N0M0 9
T3N0M0 3
T1N1M0 2
T2N1M0 14
T3N1M0 8
T4N1M0 1
T2N2 M0 3
T3N2 M0 5
61
AEG 1 – adenocarcinoma of gastroesophageal junction type 1; AEG 3 – adenocarcinoma of gastroesophageal junction type 3; Lauren (I : M : D) – Lauren (intesti-
nal : mixed : diffuse)
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Table II. Correlation between b-catenin, nuclear catenin and prognostic factors in adenocarcinoma of the esophagogas-
tric junction
m(+) n(+) m(+) n(–) (fig. 1) m(–) n(+) (fig. 2) p fOr t and n
Aeg 1 6 12 3
0.041
0.048
Lauren 4i, 1d, 1m 10i, 1d, 1m 2i, 1m
G G1- G1 G1
G2 1 G3 5 G2 1
G3 5 G3 6 G3 2
T T1 T1 4 T1 1
T2 3 T2 3 T2 2
T3 3 T3 5 T3
T4 T4 T4
N N0 1 N0 3 N0 2
N1 4 N1 9 N1 1
N2 1 N2 N2
Aeg 3    6 10   5
Lauren 4i, 1d, 1m 7i, 3d 4i, 1d
G G1 G1 G1
G2 2 G2 6 G2 4
G3 4 G3 4 G3 1
T T1 1 T1 T1 2
T2 3 T2 8 T2 3
T3 2 T3 2 T3
T4 T4 T4
N N0 3 N0 1 N0 2
N1 2 N1 6 N1 3
N2 1 N2 3 N2
Total  12 22 8
Fig. 1. Immuohistochemistry in the surgical specimen – 
reduction of b-catenin in cell membrane staining – M(+) 
N(–). Objective magnification 20×   
Fig. 2. Immuohistochemistry in the surgical specimen – 
staining of cell’s nucleus M(–) N(+).Objective magnifica-
tion 20×   
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the depth of infiltration, but did not find any connec-
tion with tumor differentiation or lymph node me-
tastases, whereas the authors observed a significant 
correlation with longer survival [11]. In our opinion 
the decisive factor for survival was the T stage. The 
role of catenin remains unclear. Its location and accu-
mulation in the cell are connected with Wnt-path-
way activation (coded group of family genes). The 
Wnt gene family influences transmission of many 
signals in physiological processes such as cell differen-
tiation, migration and transcription, but also its role 
in pathology is suggested, particularly in the process 
of carcinogenesis. The signals transmitted through 
Wnt are submitted by b-catenin and its action is 
regulated by the adenomatous polyposis coli APC/
GSK-3B complex. So stabilized catenin, controlled 
by phosphorylation process GSK-3B remains in the 
cytosol, whereas in the case of stimulation, it is trans-
ported into the cell nucleus in the form of T-cell fac-
tor complex causing cyclin D1, c-Myc, PPAR-sigma, 
and MMP 7 stimulation. Myc causes the induction 
of telomerase transcription, affecting an unidentified 
factor releasing p27 and blocking the cyclin sdk2. It 
is considered that catenin degradation may prevent 
APC and e-adherin mutations. Wnt and catenin acti-
vation may be connected to the process of oncogene-
sis and malignancy progression as well [4, 15]. In this 
study, b-catenin staining distribution in esophageal 
adenocarcinoma (on the ground of Barrett’s) type 1 
and subcardial stomach carcinoma type 3, depending 
on severity, differentiation, and Lauren’s classifica-
tion, was compared. Reduction of staining intensity 
was observed in the membranous part, while normal 
staining was observed in the cell nucleus. In this study 
a statistically significant difference in staining reduc-
tion, metastatic potential, and differentiation degree 
dependent on T stage was found. Gunther et al. 
found that nuclear expression of b-catenin may have 
a different effect on the course of rectal and colon car-
cinomas [16]. Our studies confirmed incorrect stain-
ing of b-catenin in 39 (61) patients diagnosed with 
adenocarcinoma of the esophagus type 1 and type 3. 
The difference in staining for the individual types was 
not statistically significant. No statistically signifi-
cant relation of staining reduction to patient survival 
or Lauren’s classification was observed. Czyzewska 
et al. found a statistically significant dependence of 
γ-catenin staining, Lauren’s classification intestinal 
type and degree of stomach cancer differentiation but 
did not find a correlation with survival. They found 
a strong correlation between stage of stomach can-
cer and metastatic potential [17]. Analyzing nuclear 
staining in tumor type 1 (AEG 1) and type 3 (AEG 3) 
and referring them to Lauren’s classification, they 
found them in 13 (28%) patients in Lauren’s type 1 
(7 in AEG 1) and 6 in AEG 3. Lee et al., analyzing pa-
tients with early stage stomach cancer, found that re-
location, that is an increased level of b-catenin in the 
cytoplasm and cell nucleus, among patients with in-
testinal mucin phenotype in comparison with gastric 
mucin phenotype in stomach cancer, concerned 30% 
of patients. At the same time they found a lack of 
association between loss of APC heterozygosity and 
relocation, while attributing the role of hypermeth-
ylation in the process of b-catenin relocation [18]. 
Woo et al. reported that staining of the nucleus and 
relocation took place in diffuse type stomach cancer 
in 27% of patients. The above is not confirmed by 
Ogasawa et al. They reported that staining of the cell 
nucleus occurred more often in intestinal type stom-
ach cancer than in diffuse type [19, 20]. It seems that 
B-catenin relocation into the cell nucleus is possible 
due to c-Myc and cyclin D1 activation [21]. Bondi 
et al., analyzing colon cancer, did not find a correla-
tion between b-catenin relocation and c-Myc or cy-
clin D1 activation. The authors noted that b-catenin 
relocation constituted metastatic potential while not 
noting this correlation in relation to c-Myc, cyclin 
D1 and γ-catenin. They assumed that the reason for 
that is metalloprotease, which is a target gene for the 
b-catenin/TCF pathway in colon cancer and can be 
activated independently from c-Myc and cyclin D1. 
Overexpression of MMP-7 is found in 80% of colon 
cancer cases and is an important factor in invasion 
and metastases [22]. The role of b-catenin relocation 
into the cell nucleus is emphasized by other authors, 
who prove its influence on malignant transformation 
in colon and pancreatic carcinomas [23, 24]. Incor-
rect b-catenin staining is observed in other organs 
such as liver, lungs, pancreas, and colon, although the 
mechanism of its activation can vary [25, 26, 27, 28]. 
Xianhua et al., analyzing the survival in 262 patients 
diagnosed with non-small cell lung cancer observed 
incorrect b-catenin staining in 189 (76%) patients, 
in correlation with Wnt1, overexpression c-Myc, cy-
clin D1, and p53. In the analyzed group, patients in 
whom positive staining was found had significantly 
shorter survival, but in multifactorial analysis Wnt1 
expression constituted an independent prognostic 
factor of survival [25, 29].
In conclusion, we observed a correlation of b-cat-
enin reduction with T and N stage, without an influ-
ence on survival. Its relocation into the cell nucleus 
concerned 20 patients. However, the role of b-cat-
enin in relation to progression of malignancy remains 
unclear. The biological effect of staining reduction 
provides for an increased metastatic potential.
The authors declare no conflict of interest.
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